Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Category list : Antiviral agents

Sort by: Newest first Oldest first A-Z Z-A

  • Micrograph of human immunodeficiency virus (HIV) virions

    High-risk women need more frequent doses of HIV drugs Subscription

    8 MAR 2016 16:31

    Researchers say more frequent pre-exposure prophylaxis is required to protect women from HIV.

  • Stethoscope and new born baby

    Exposure to atazanavir in womb linked to neurodevelopmental problems in infants Subscription

    2 MAR 2016 15:38 By Janna Lawrence

    Babies exposed to the HIV drug atazanavir in the womb may have impaired language and social-emotional development at one year, suggests a new study.

  • International study finds high proportion of HIV patients were resistant to cART drug tenofovir. In the image, micrograph of HIV budding from a lymphocyte

    HIV resistance to tenofovir surprisingly common Subscription

    11 FEB 2016 9:56

    International study finds high proportion of HIV patients were resistant to cART drug tenofovir.

  • Daklinza licence extension Subscription

    9 FEB 2016 12:04

    Daklinza (daclatasvir; Bristol Myers Squibb), used in combination with other drugs to treat hepatitis C, has been approved for extended use for patients co-infected with HIV and also post liver transplantation by the European Medicines Agency. 

  • Antivirals in immunocompromised patients Subscription

    8 FEB 2016 14:19

    Public Health England (PHE) has issued updated guidance on prophylaxis of influenza in severely immunocompromised patients. It now recommends that zanamavir is used as the first line antiviral instead of oseltamivir. The guidance can be accessed via the

  • Researchers have now shed light on how the TRIM5α protein (illustration pictured) targets the HIV-1 retrovirus and triggers its degradation and activates the innate immune system pathways

    Researchers unravel function of HIV defence protein Subscription

    5 FEB 2016 10:34

    Researchers investigate why TRIM5α protein lost ability to degrade HIV in rhesus monkey study.

  • Targeting Hepatitis C: How new treatments work

    Targeting hepatitis C — how new treatments work Subscription

    28 JAN 2016 16:35 By Dawn Connelly

    There are >185 million people with hepatitis C infection worldwide but new treatments mean that most people with access to therapy can now be cured. 

  • Harvoni for hepatitis C genotypes 5 and 6 Subscription

    18 JAN 2016 13:58

    The summary of product characteristics for Harvoni (ledipasvir and sofosbuvir; Gilead), used to treat hepatitis C, has been updated to include information about posology and the method of administration for patients with genotype 5 or 6 — it previously only included genotypes 1 and 4. 

  • Offering men who have sex with men antiretroviral therapy as pre-exposure prophylaxis (PrEP) is necessary if the UK is to achieve a marked reduction in the annual rate of HIV infections by the end of 2020. Pictured, a man holds up a PrEP (Truvada) pill

    Pre-exposure prophylaxis necessary to reduce HIV infection rate among MSM Subscription

    14 JAN 2016 15:01

    Offering men who have sex with men antiretroviral therapy as pre-exposure prophylaxis is necessary if the UK is to achieve a marked reduction in the annual rate of HIV infections by the end of this decade, according to new research.

  • Antiviral prescribing for influenza Subscription

    12 JAN 2016 16:25

    The Department of Health (DH) has said that antiviral medications may now be prescribed at NHS expense for prophylaxis and treatment of influenza. This follows a recent increase in influenza virus activity. Antivirals should be considered for patients at risk of severe complications from influenza, or if they are in a “clinical at risk group”. More information can be found

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.